Advertisement

Search Results

Advertisement



Your search for Matthew Stenger matches 46 pages

Showing 1 - 46


sarcoma

Pazopanib in Advanced Extraskeletal Myxoid Chondrosarcoma

Findings from a cohort of a phase II study reported by Stacchiotti et al in The Lancet Oncology indicated activity of the antiangiogenic agent pazopanib in advanced extraskeletal myxoid chondrosarcoma. As noted by the investigators, this rare sarcoma has low sensitivity to cytotoxic chemotherapy,...

sarcoma

Addition of Preoperative NBTXR3 to Radiotherapy in Locally Advanced Soft-Tissue Sarcoma

In the phase II/III Act.In.Sarc trial reported in The Lancet Oncology, Bonvalot et al found that preoperative addition of the radioenhancer hafnium oxide nanoparticle NBTXR3 to radiotherapy may improve outcomes in patients with locally advanced soft-tissue sarcoma. The agent acts to increase...

sarcoma

Cediranib in Alveolar Soft-Part Sarcoma

In the phase II CASPS trial reported in The Lancet Oncology, Judson et al found evidence of activity of cediranib in alveolar soft-part sarcoma. In the double-blind trial, 48 patients from 12 sites in the United Kingdom, Spain, and Australia were randomly assigned 2:1 between July 2011 and July...

sarcoma

SARC024: Regorafenib in Metastatic Osteosarcoma

In the phase II SARC024 trial in sarcoma subtypes reported in the Journal of Clinical Oncology, Davis and colleagues found that regorafenib improved progression-free survival vs placebo in the cohort of patients with metastatic osteosarcoma. The double-blind study included 42 patients from 12 U.S. ...

sarcoma
immunotherapy

Axitinib Plus Pembrolizumab in Advanced Sarcomas

In a phase II trial reported in The Lancet Oncology, Wilky et al found evidence of activity of axitinib plus pembrolizumab in advanced sarcomas, including alveolar soft-part sarcoma. Study Details The study involved 33 patients with advanced or metastatic sarcomas, including alveolar soft-part...

sarcoma

Phase II Study of Regorafenib in Metastatic Osteosarcoma

As reported in the Journal of Clinical Oncology by Davis et al, outcomes in the osteosarcoma cohort of the phase II SARC024 trial indicated a progression-free survival benefit with regorafenib vs placebo in previously treated metastatic osteosarcoma. Study Details The randomized...

sarcoma

Clinical Significance of Indeterminate Pulmonary Nodules at Diagnosis in Pediatric Rhabdomyosarcoma

In a study reported in the Journal of Clinical Oncology, Vaarwerk et al found that presence of indeterminate pulmonary nodules at diagnosis of pediatric rhabdomyosarcoma did not adversely affect treatment outcome in otherwise localized disease. The study involved 316 patients from the European...

sarcoma
issues in oncology

Regionalization of Surgery for Retroperitoneal Sarcoma Surgery to High-Volume Hospitals

In a study reported in the Journal of Oncology Practice, Villano et al found that regionalization of retroperitoneal sarcoma surgery—recognized as a complex cancer surgery—to high-volume hospitals has been slower than that observed for similarly complex pancreatic cancer surgery over...

sarcoma

Regorafenib in Previously Treated Metastatic Osteosarcoma

In a phase II trial reported in The Lancet Oncology, Duffaud et al found evidence of activity of regorafenib (Stivarga) in a cohort of adult patients with previously treated metastatic osteosarcoma. This noncomparative, double-blind trial involves 4 cohorts of patients, consisting of those with...

sarcoma

Factors Affecting Prognosis in Localized Paratesticular Rhabdomyosarcoma

In a study reported in the Journal of Clinical Oncology, Walterhouse et al found that age ≥ 10 years at diagnosis and tumor size > 5 cm are adverse prognostic features in localized paratesticular rhabdomyosarcoma. Study Details The study was a pooled analysis of data from North American and ...

sarcoma

High-Dose Chemotherapy and Autologous SCT vs Standard Chemotherapy in Localized High-Risk Ewing Sarcoma

As reported in the Journal of Clinical Oncology by Whelan et al, combined trials (EURO-EWING99 and Ewing-2008) have shown evidence of improved outcomes with high-dose therapy with busulfan and melphalan (BuMel) and autologous stem cell transplant (SCT) vs standard chemotherapy with vincristine,...

sarcoma

Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide in Pediatric Intermediate-Risk Rhabdomyosarcoma

In a phase III Children’s Oncology Group study reported in the Journal of Clinical Oncology, Hawkins et al found that substituting vincristine and irinotecan (VI) for half of vincristine, dactinomycin, and cyclophosphamide (VAC) courses did not improve event-free survival in pediatric...

sarcoma

Addition of Dose-Intensified Doxorubicin to Standard Chemotherapy in Rhabdomyosarcoma

As reported by Bisogno et al in The Lancet Oncology, a phase III trial (EpSSG RMS 2005) has shown no benefit of adding doxorubicin to standard IVA (ifosfamide, vincristine, dactinomycin) in 3-year event-free survival among patients with high-risk rhabdomyosarcoma. Study Details In the open-label...

sarcoma

Trametinib Treatment for Histiocytic Sarcoma With an Activating MAP2K1 Mutation

In a letter to the editor in The New England Journal of Medicine, Gounder et al described the successful treatment of a patient with histiocytic sarcoma and an activating MAP2K1 (MEK1) mutation with the MAPK kinase 1 and 2 inhibitor trametinib (Mekinist). As noted by the authors, patients with...

sarcoma

Neoadjuvant Chemotherapy With or Without Regional Hyperthermia in Localized High-Risk Soft-Tissue Sarcoma

As reported in JAMA Oncology by Issels et al, long-term follow-up of the phase III EORTC 62961-ESHO 95 trial has shown improved outcomes with the addition of regional hyperthermia to neoadjuvant chemotherapy in patients with high-risk soft-tissue sarcoma. Study Details In the open-label trial,...

sarcoma
immunotherapy

Nivolumab With or Without Ipilimumab in Advanced Sarcoma

In the phase II Alliance A091401 trial reported in The Lancet Oncology, D’Angelo et al found evidence of activity of nivolumab plus ipilimumab in advanced sarcoma. Study Details The study comprised two noncomparative randomized phase II trials in which a total of 85 eligible patients...

sarcoma

Immunotherapy for Advanced Soft-Tissue and Bone Sarcoma

The phase II SARC028 trial has shown activity of pembrolizumab (Keytruda) in some subtypes of advanced sarcoma. These findings were reported by Tawbi et al in The Lancet Oncology. Study Details In the study, 84 patients with advanced soft-tissue sarcoma aged ≥ 18 years (n = 42) or bone sarcoma ...

sarcoma

First-Line Gemcitabine/Docetaxel vs Doxorubicin in Advanced Soft-Tissue Sarcoma

In the UK-Swiss phase III GeDDiS trial, the combination of gemcitabine and docetaxel did not significantly improve progression-free survival vs doxorubicin in first-line treatment of locally advanced or metastatic soft-tissue sarcoma. Findings were reported in The Lancet Oncology by Seddon et al....

sarcoma

Eribulin vs Dacarbazine in Advanced Liposarcoma Subgroup

The subgroup analysis of outcomes among patients with advanced liposarcoma from a pivotal phase III trial comparing eribulin (Halaven) vs dacarbazine in previously treated liposarcoma or leiomyosarcoma was reported in the Journal of Clinical Oncology by Demetri et al. Overall, the phase III trial...

sarcoma

Adding Evofosfamide to Doxorubicin in Advanced Soft-Tissue Sarcoma

A phase III trial (TH CR-406/SARC021) has shown no survival benefit of adding evofosfamide to doxorubicin in the first-line treatment of locally advanced unresectable or metastatic soft-tissue sarcoma. Trial results were reported in The Lancet Oncology by Tap et al. Evofosfamide is a...

sarcoma

No Benefit Reported With Addition of Palifosfamide to Doxorubicin in Metastatic Soft-Tissue Sarcoma

In the phase III PICASSO III trial reported in the Journal of Clinical Oncology, Ryan et al found that adding palifosfamide to doxorubicin did not prolong progression-free survival among patients with metastatic soft-tissue sarcoma. Palifosfamide is the active metabolite of ifosfamide. In the...

sarcoma

Is Regorafenib Active in Advanced Nonadipocytic Soft-Tissue Sarcoma?

Mir et al found that regorafenib (Stivarga) was active in patients with advanced nonadipocytic soft-tissue sarcoma previously treated with an anthracycline, according to a French-Austrian phase II trial reported in The Lancet Oncology. Regorafenib should be evaluated further in this setting, the...

sarcoma

Early FDG-PET and Volumetric Analysis May Be Best Predictors of Benefit in Ewing Sarcoma

In a study reported in the Journal of Clinical Oncology, Koshkin et al found that among anatomic and functional imaging modalities, volumetric analysis and outcome with early 18F-fluorodeoxyglucose (FDG)–positron-emission tomography (PET) were the best predictors of benefit in patients with...

sarcoma

Does Intensified Postoperative Chemotherapy for High-Grade Osteosarcoma Benefit Poor Responders to Preoperative Therapy?

In a phase III trial (EURAMOS-1) reported in The Lancet Oncology, Marina et al found no improvement in event-free survival by adding postoperative ifosfamide/etoposide to cisplatin, doxorubicin, and methotrexate in patients with newly diagnosed high-grade osteosarcoma who responded poorly to...

sarcoma

Study Finds Genetic Risk Variants in Half of Patients With Sarcoma

In an international genetic study (International Sarcoma Kindred Study) reported in The Lancet Oncology, Ballinger et al found that approximately half of all patients with sarcoma harbored potentially pathogenic monogenic and polygenic variation in known and novel cancer genes. Study Details The...

sarcoma

Study Finds Adding Olaratumab to Doxorubicin Improves Survival in Advanced Soft-Tissue Sarcoma

The addition of olaratumab, an anti–platelet-derived growth factor receptor alpha (anti–PDGFRα) antibody, to doxorubicin resulted in prolonged progression-free and overall survival in the phase II evaluation of patients with advanced soft-tissue sarcoma, according to findings...

solid tumors
sarcoma

French Phase III Trial Shows No Benefit of Adding Zoledronate to Chemotherapy and Surgery in Osteosarcoma

In the French phase III OS2006 trial reported by Piperno-Neumann et al in The Lancet Oncology, the addition of zoledronate to chemotherapy and surgery provided no event-free survival benefit in the treatment of patients with newly diagnosed high-grade osteosarcoma. Study Details In the open-label ...

sarcoma

Survival Benefit Reported With Radiotherapy vs Surgery Alone in Retroperitoneal Sarcoma

In a study using National Cancer Data Base data reported in The Lancet Oncology, Nussbaum et al found that preoperative and postoperative radiotherapy improved overall survival vs surgery alone in patients with retroperitoneal sarcoma. Study Details The study consisted of case-control, propensity ...

solid tumors
sarcoma

Outcomes With Palbociclib at Altered Dose and Schedule in Liposarcoma

In a single-center phase II trial reported in JAMA Oncology, Dickson et al found that changing the dose and schedule of palbociclib (Ibrance) from those in a previous phase II trial appeared to maintain activity while potentially reducing hematologic adverse effects in patients with advanced...

sarcoma

Nomograms for Predicting Survival and Distant Metastasis After Resection of Localized Soft-Tissue Sarcoma of the Extremities

As reported in The Lancet Oncology, Callegaro et al have developed nomograms to predict overall survival and risk of distant metastases in patients undergoing resection of soft-tissue sarcomas of the extremities. Study Details The study involved data from a development cohort of 1,452 consecutive ...

sarcoma

Eribulin Improves Overall Survival vs Dacarbazine in Advanced Liposarcoma or Leiomyosarcoma

In a phase III trial reported in The Lancet, Schöffski et al found that eribulin improved overall survival vs dacarbazine in patients with advanced or metastatic soft-tissue sarcoma who had received at least two prior systemic treatments for advanced disease. Outcome in the subgroup with...

breast cancer
hematologic malignancies
leukemia
sarcoma

Increased Breast Cancer Risk Reported in Childhood Sarcoma and Leukemia Survivors With No History of Chest Radiotherapy

In an analysis of the Childhood Cancer Survivor Study reported in the Journal of Clinical Oncology, Henderson et al found that childhood survivors of sarcoma and leukemia with no history of chest radiotherapy were at an increased risk of breast cancer. Increased Risk The study included data from...

sarcoma

Good Outcomes With Intensive, Interval-Compressed Chemotherapy and Irinotecan as Radiosensitizer in High-Risk Rhabdomyosarcoma

As reported in the Journal of Clinical Oncology by Weigel et al in the Children’s Oncology Group, a strategy of dose intensification and interval compression, use of the most active agents determined in phase II window studies, and use of irinotecan as a radiation sensitizer has been found to ...

sarcoma

Phase IIb Trial Shows Improved Progression-Free Survival With First-Line Aldoxorubicin vs Doxorubicin in Advanced Soft-Tissue Sarcoma

In a randomized phase IIb trial reported in JAMA Oncology, Chawla et al found that aldoxorubicin—a novel albumin-binding prodrug of doxorubicin—produced longer progression-free survival than doxorubicin as first-line treatment for metastatic or locally advanced unresectable soft-tissue...

sarcoma

Improved Progression-Free Survival With Trabectedin vs Dacarbazine After Conventional Chemotherapy in Advanced Liposarcoma or Leiomyosarcoma

In a phase III trial reported in the Journal of Clinical Oncology, Demetri et al found that treatment with trabectedin significantly improved progression-free survival vs dacarbazine in patients with advanced liposarcoma or leiomyosarcoma after prior conventional chemotherapy. Interim analysis of...

sarcoma

French Phase II Trial Suggests No Benefit of Adding Bevacizumab to Paclitaxel in Advanced Angiosarcoma

In a French phase II trial reported in the Journal of Clinical Oncology, Ray-Coquard et al found no apparent benefit of paclitaxel plus bevacizumab (Avastin) compared with weekly paclitaxel in patients with inoperable locally advanced or metastatic angiosarcoma. Study Details In this...

sarcoma
sarcoma

Addition of Interferon Alfa-2b to MAP Does Not Meet Event-Free Survival Objective in Osteosarcoma With Good Response to Preoperative MAP

In the phase III EURAMOS-1 trial reported in the Journal of Clinical Oncology, Bielack et al found that the addition of postoperative pegylated interferon alfa-2b (Pegintron, Sylatron) to MAP (methotrexate, doxorubicin, and cisplatin) in patients with osteosarcoma showing good histologic response...

sarcoma

Persistence of HER2-Specific CAR T Cells in HER2‑Positive Sarcoma

In a phase I/II study reported in Journal of Clinical Oncology, Ahmed et al found that infusion of T cells expressing HER2-specific chimeric antigen receptor (CAR) with a CD28.ζ signaling domain (HER2-CAR T cells) could produce persistent CAR T cell levels for ≥ 6 weeks in patients with...

gynecologic cancers
sarcoma

No Benefit of Adding Bevacizumab to First-Line Gemcitabine-Docetaxel in Metastatic Uterine Leiomyosarcoma

In a phase III NRG Oncology/Gynecologic Oncology Group (GOG) trial reported in the Journal of Clinical Oncology, Hensley et al found no benefit of adding bevacizumab (Avastin) to first-line gemcitabine-docetaxel in patients with metastatic uterine leiomyosarcoma. Study Details In this...

sarcoma

Reduction in Late Toxicities With Preoperative Image-Guided Radiation Therapy to Reduced Target Volume in Patients With Extremity Sarcoma

As reported in the Journal of Clinical Oncology by Wang et al, the incidence of late toxicity among patients with extremity soft-tissue sarcoma receiving preoperative image-guided radiotherapy to a reduced target volume in the phase II Radiation Therapy Oncology Group (RTOG) 0630 trial was lower...

sarcoma

Sorafenib Plus Everolimus Shows Some Activity in Progressive Unresectable High-Grade Osteosarcoma

In an Italian Sarcoma Group phase II study reported in The Lancet Oncology, Grignani et al found that the combination of sorafenib (Nexavar) and everolimus (Afinitor) was active in unresectable high-grade osteosarcoma progressing after standard treatment, but did not produce the study goal of ≥...

sarcoma

Shorter-Duration Therapy Including Lower-Dose Cyclophosphamide Preserves Efficacy in Newly Diagnosed Low-Risk Rhabdomyosarcoma

Intergroup Rhabdomyosarcoma Study Group (IRSG) studies have shown improved failure-free survival with VAC (vincristine, dactinomycin, and cyclophosphamide) given with a total cumulative cyclophosphamide dose of 26.4 g/m2 compared with VA (vincristine and dactinomycin) in patients with subset 1...

sarcoma

Reduced Local Recurrence With Intensity-Modulated vs External-Beam Radiation Therapy in Primary Soft-Tissue Sarcomas of the Extremity

There are no large-scale direct comparisons of outcomes with intensity-modulated radiation therapy vs conventional external-beam radiation therapy in patients with soft-tissue sarcoma of the extremity. In a single-institution experience reported in the Journal of Clinical Oncology, Folkert et al at ...

sarcoma

Phase II Study Shows Activity of Hypoxia-Activated Alkylating Prodrug in Combination With Doxorubicin in Advanced Soft-Tissue Sarcoma

In a phase II study reported in the Journal of Clinical Oncology, Chawla et al found that the combination of a hypoxia-activated alkylating prodrug (TH-302) and doxorubicin was active in first-line treatment of advanced soft-tissue sarcoma. TH-302 is a prodrug of the cytotoxic alkylating agent...

sarcoma

Cyclophosphamide Noninferior to Ifosfamide as Part of Consolidation Treatment in Standard-Risk Ewing Sarcoma

In a European phase III noninferiority trial (Euro-EWING99-R1) reported in the Journal of Clinical Oncology, Le Deley et al found that cyclophosphamide was noninferior in event-free survival vs ifosfamide in combination with vincristine/dactinomycin as consolidation therapy in patients with...

sarcoma

No Overall Survival Benefit of First-Line Doxorubicin Plus Ifosfamide vs Doxorubicin Alone in Advanced Soft-Tissue Sarcoma

In the open-label, phase III EORTC 62012 trial reported in The Lancet Oncology, Judson et al found that doxorubicin plus ifosfamide was not associated with any overall survival advantage compared with doxorubicin alone in patients with advanced or metastatic soft-tissue sarcoma. Progression-free...

Advertisement

Advertisement



Advertisement